Clinical Trials Logo

ROS1 Fusion Positive clinical trials

View clinical trials related to ROS1 Fusion Positive.

Filter by:
  • None
  • Page 1

NCT ID: NCT03868423 Withdrawn - Clinical trials for Metastatic Malignant Solid Neoplasm

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Start date: March 20, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02587650 Terminated - Clinical trials for ALK Fusion Protein Expression

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Start date: March 26, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.